Wells Fargo & Company Boosts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $95.00

Halozyme Therapeutics (NASDAQ:HALO) had its price objective boosted by investment analysts at Wells Fargo & Company from $75.00 to $95.00 in a report issued on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Wells Fargo & Company‘s price target indicates a potential downside of 3.95% from the company’s current price.

A number of other equities research analysts have also recently issued reports on HALO. Weiss Ratings raised Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 31st. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and set a $110.00 price objective for the company in a research note on Friday. Morgan Stanley decreased their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, July 21st. Nine analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $89.60.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $98.91 on Friday. Halozyme Therapeutics has a fifty-two week low of $61.22 and a fifty-two week high of $96.77. The business has a 50-day moving average of $75.74 and a two-hundred day moving average of $71.25. The stock has a market capitalization of $11.73 billion, a P/E ratio of 34.86, a P/E/G ratio of 0.35 and a beta of 0.85. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the company posted $1.54 EPS. The firm’s revenue was up 47.7% on a year-over-year basis. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities research analysts predict that Halozyme Therapeutics will post 7.54 EPS for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $67.58, for a total transaction of $1,351,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at $51,886,572.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $76.71, for a total value of $124,653.75. Following the completion of the sale, the director directly owned 42,044 shares of the company’s stock, valued at $3,225,195.24. This represents a 3.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 72,477 shares of company stock worth $5,102,643 over the last three months. 2.50% of the stock is currently owned by insiders.

Institutional Trading of Halozyme Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of HALO. Measured Wealth Private Client Group LLC grew its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 343 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Halozyme Therapeutics during the 2nd quarter worth approximately $28,000. Harbour Investments Inc. grew its holdings in shares of Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 372 shares in the last quarter. Finally, Clearstead Advisors LLC increased its position in shares of Halozyme Therapeutics by 64.8% during the fourth quarter. Clearstead Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 331 shares during the period. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Strong Q2 results: Halozyme reported adjusted EPS of $2.28, above the roughly $1.79-$1.82 consensus range, while revenue reached $481 million versus estimates of approximately $402 million. Revenue increased 48% year over year, and royalty revenue rose 50% to $308 million. Halozyme Reports Record Second Quarter 2026 Results
• Positive Sentiment: Raised full-year guidance: The company now expects 2026 revenue of $1.835 billion-$1.910 billion, adjusted EBITDA of $1.225 billion-$1.280 billion and non-GAAP EPS of $8.65-$9.00. The EPS outlook is above the approximately $8.02 analyst consensus, signaling stronger expected profitability and growth.
• Positive Sentiment: Additional collaboration momentum: Halozyme signed five new ENHANZE and Hypercon collaboration agreements year to date, exceeding its full-year goal of three. The agreements support the company’s recurring royalty and licensing growth strategy. Halozyme Collaboration Agreements
• Positive Sentiment: Analyst sentiment improved: Leerink Partners upgraded HALO from “market perform” to “outperform” with a $110 price target. HC Wainwright also raised its target from $95 to $115 and maintained a “buy” rating, implying substantial upside from the current trading level. Benzinga Analyst Actions
• Neutral Sentiment: The company’s earnings-call presentation and transcript provide additional details on the quarter, collaboration pipeline and operating outlook. Q2 2026 Earnings Presentation

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.